Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report (IMAGE)

Impact Journals LLC

Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report

Caption

Figure 2: Radiographic response imaging to pralsetinib plus lorlatinib. (A) Computed tomography (CT) during lorlatinib treatment revealing right cervical lymph node. (B) CT showing decrease in lymph node size with necrosis after addition of pralsetinib. (C) Chest CT during lorlatinib treatment showing right-sided pleural effusion. (D) Chest CT showing decrease in effusion after pralsetinib treatment. Images A and C were taken on day 1135 post-diagnosis. Images B and D were taken on day 1268.

Credit

Copyright: © 2025 Wu and Iams.

Usage Restrictions

With credit to the original source.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.